FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

SWIFT Strengthens Blockchain-Based Shared Ledger for Real Transactions This Year

The financial messaging service aims to integrate blockchain technology in operations.Highlights: SWIFT plans to launch a blockchain-based shared...
FinTech

Nium Launches Dual-Network Stablecoin Card Issuance Platform

New platform aims to streamline stablecoin card issuance and enhance user experience.Highlights: Nium unveils a new platform for...
FinTech

Wise Launches UK Current Accounts, Expanding Financial Services

The new accounts aim to simplify banking for UK customers.Highlights: Wise introduces current accounts to UK market.The new...
FinTech

Lloyds Bank Strengthens Research on AI Impact in Software Engineering

The collaboration aims to explore the future of technology in banking.Highlights: Lloyds Bank partners with the University of...